3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Unknown
2
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
6
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Kidney Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Skin Neoplasms
1
Recurrence
1
Radiation Injuries
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Pleural Effusion, Malignant
1
Platinum Resistant Ovarian Cancer
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Melanoma
1
Lymphopenia
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Hot Flashes
1
Hodgkin Disease
1
Gangliosidosis, GM1
1
Gangliosidoses
1
Fatigue
1
Interventions
Carboplatin
49
Pemetrexed
38
Cisplatin
34
Radiotherapy
32
Docetaxel
31
Gemcitabine
25
Paclitaxel
24
Nivolumab
18
pembrolizumab
15
Etoposide
15
Radiosurgery
13
Erlotinib Hydrochloride
11
Bevacizumab
11
Magnetic Resonance Spectroscopy
10
Vinorelbine
9
Radiation
9
Cyclophosphamide
7
durvalumab
6
Gefitinib
6
Fluorodeoxyglucose F18
6
Celecoxib
6
atezolizumab
5
Oxaliplatin
5
Irinotecan
5
Immunoglobulin G
5
Drug Therapy
5
Disulfides
5
Dexamethasone
5
Chemotherapy, Adjuvant
5
vandetanib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lung Neoplasms
×
Sodium Chloride
×
Clear all
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts